Cosentyx Drug Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Cosentyx Drug market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to factors such as FDA approval and early market entry, the clinical efficacy and safety profile of Cosentyx, the shift toward biologics, real-world data supporting its benefits, and global regulatory approvals.

Market growth during the forecast period is driven by the increasing prevalence of autoimmune diseases, the expansion of approved indications, advancements in biologic therapies, favorable reimbursement policies, and strong clinical outcomes. Key trends in the forecast period include expanding applications for autoimmune diseases, a shift toward personalized medicine, and the continued dominance of subcutaneous administration and research and development in new therapeutic areas.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the cosentyx market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells and tissues. This rise can be attributed to factors such as genetic predisposition, environmental influences (e.g., infections and pollutants), and lifestyle changes, including higher stress levels and dietary shifts. Cosentyx (secukinumab) plays a vital role in treating autoimmune conditions by targeting and inhibiting interleukin-17A, a cytokine involved in the inflammatory process. This helps reduce symptoms, improve the quality of life, and manage conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis effectively. For example, in July 2023, Public Health Scotland reported that the number of newly diagnosed multiple sclerosis (MS) patients increased by 87.2% in 2022, highlighting the growing prevalence of autoimmune diseases and driving demand for treatments like cosentyx.

Rising healthcare expenditure is expected to propel the cosentyx market. Increased spending on healthcare services, driven by an aging population, chronic diseases, advanced medical technology, and higher drug prices, has led to more investment in biologic therapies like Cosentyx. The biologic drug is especially used in managing moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, improving patient outcomes through targeted therapy. In May 2024, the UK’s Office for National Statistics reported a 5.6% rise in total healthcare expenditure from 2022 to 2023, further highlighting the increasing financial commitment to healthcare and biologic treatments.

A key trend in the cosentyx market is the development of advanced biological therapies to address unmet medical needs and improve treatment efficacy. Cosentyx is part of this trend, with a focus on managing chronic autoimmune conditions using targeted therapies. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, received FDA approval for Cosentyx as the first new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly a decade. This approval represents a significant advancement in HS treatment, demonstrating Cosentyx's growing role in autoimmune disease management and expanding its market reach.

Key player operating in the cosentyx drug market is Novartis AG.

North America was the largest region in the cosentyx drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cosentyx drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cosentyx drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cosentyx (secukinumab) is a prescription biologic medication developed by Novartis. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation. Cosentyx is primarily used to treat autoimmune conditions such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Administered via subcutaneous injection, it helps reduce inflammation, alleviate skin symptoms, and prevent joint damage. The drug has demonstrated effectiveness in improving the quality of life for patients suffering from these chronic conditions.

The primary indications for cosentyx include hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Hidradenitis suppurativa is a chronic skin condition that causes painful lumps, abscesses, and scarring, typically in areas with sweat glands such as the underarms and groin. The routes of administration include subcutaneous injection and intravenous infusion, with distribution channels encompassing hospital pharmacies, online pharmacies, and retail pharmacies.

The cosentyx drug market research report is one of a series of new reports that provides cosentyx drug market statistics, including cosentyx drug industry global market size, regional shares, competitors with a cosentyx drug market share, detailed cosentyx drug market segments, market trends and opportunities, and any further data you may need to thrive in the cosentyx drug industry. This cosentyx drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cosentyx drug market consists of sales oflyophilized powder, and self-administered autoinjector. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.